Better Treatment Option for some Low-Grade Glioma Patients Becomes a Reality

March 16 marked a historic day for the pediatric brain cancer community with the passing of the first-ever drugs approved by the FDA to treat children with certain types of brain cancer. The two approved drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), created and manufactured by pharmaceutical company, Novartis, were authorized to be used in combination in first-line treatment of low-grade glioma (LGG) with a BRAF V600E mutation in kids one year and up. This came after the TADPOLE trial showed an overall response rate of 47% and median progression-free survival of 20.1 months for the Tafinlar + Mekinist combination compared to 11% overall response rate and 7.4 months for standard of care, according to Novartis


It is important to note that until last week, there had never been any drugs approved specifically for use in children battling pediatric brain cancer. The additional approval of the two drugs in liquid form is another win, as it provides an accessible option to patients as young as one year old. Dr. Brian Rood, Director, Clinical Neuro-Oncology, Medical Director, Brain Tumor Institute, and LBF Scientific advisor, said in a statement, “Over the past several years, the promise of molecularly targeted therapy has begun to be realized in the treatment of BRAF-altered pediatric low-grade glioma. The FDA approval of Dabrafenib and Trametinib for a subset of LGG represents a milestone in the advancement of treatment for these tumors, one that we hope will be just the first for these types of drugs for pediatric brain tumor therapy.” 


While this milestone is historic and shows the progress being made for our smallest warriors battling the deadliest disease in children, there is still more work to do. The Lilabean Foundation for Pediatric Brain Cancer Research (LBF) is proud to support collaborative research efforts for all types of childhood brain cancer. While LBF is hopeful that this is the beginning of many breakthroughs in the pediatric brain cancer space, it is important to note that there are many different types of brain cancer that affect children and over 100 subtypes. Certain brain cancers, such as Diffuse Intrinsic Pontine Glioma (DIPG), Glioblastoma Multiforme (GBM), and others, still have no cure and are fatal to 99% of children diagnosed. We celebrate this milestone but understand there is still more work to do. 


The approval of these drugs offers hope for a future where there are treatment options and personalized medicine for ALL children diagnosed with pediatric brain cancer. Founder and Executive Director Nicole Giroux said in a statement, “The recent approval by the FDA of Tafinlar + Mekinist shows that we, as a pediatric brain cancer community, are making strides towards our common goal of safer and more effective treatment options. For 12 years, LBF has been dedicated to evaluating research and clinical trials for childhood brain cancer. This FDA approval gets us one step closer to not just saving lives but to giving our children a chance to both survive AND thrive.”

Kelly Barch headshot
December 1, 2025
The Lilabean F oundation (LBF) is thrilled to announce the appointment of Kelly Barch as our new Executive Director. Kelly will work closely with our Founder and President, Nicole Giroux , to advance the mission of the Lilabean Foundation and deepen our impact for children and families affected by pediatric brain cancer. Kelly is a mission-driven leader with more than 20 years of experience building programs, strengthening teams, and driving meaningful change across organizations. She spent 16 years at the National Cancer Institute, where she led enterprise-wide recognition programs, executive recruitment efforts, high-profile events, and cross-functional workforce initiatives. In addition to her public service, Kelly is the co-owner of Clotacin, a family-owned wellness company providing high-quality nutritional support to individuals affected by blood disorders. She oversaw operations, customer experience, and brand development, helping expand the company’s reach and impact. A lifelong Washingtonian, Kelly lives in Kensington with her husband, Justin, their children, Taylor and Beau, and their dog, Boudreaux. Outside of work, she loves staying active with her family and cheering on her alma mater, the LSU Tigers. When asked what excites her most about this new chapter, Kelly shared: “I am honored to step into the role of Executive Director and excited to bring my passion for service to the Lilabean Foundation. The opportunity to fund critical pediatric brain cancer research and help raise awareness means so much to me, and I am truly grateful to be part of this mission.” Please join us in warmly welcoming Kelly to the Lilabean Foundation. We look forward to the leadership, energy, and heart she will bring to this work!
November 12, 2025
On November 1, 2025, the Lilabean Foundation for Pediatric Brain Cancer Research (LBF) hosted its 14th Annual Fall Ball at The Schuyler at the Hamilton Hotel in Washington, D.C., raising over $1.1 million to support vital pediatric brain cancer research. This fundraising milestone reflects the unwavering commitment of the foundation’s community and partners to improve outcomes for children diagnosed with brain cancer. The evening was one of celebration and remembrance, as we honored three cherished LBF Heroes—Cameron, Kasey, and Reed—though their lives were far too short, their strength, joy, and bravery continue to guide our mission and fuel our determination. The evening’s program was filled with heartfelt speeches that reminded guests of the night’s true purpose. LBF Founder and President Nicole Giroux opened the program, sharing, “Studies say that we can go weeks without food, days without water, minutes without oxygen, but we can’t LIVE a MOMENT without hope. Your presence here tonight gives me and so many others immeasurable hope. Hope is what propels us forward. Hope gives us strength to endure hardship and believe in a better future.” The first award of the night was the LBF “Cam’s Crew” Volunteer of the Year Award , presented to the Behr Family . Evan and Caitlin Behr, along with their family, have been deeply involved with LBF since 2021, generously sharing their time, expertise, and resources. LBF is deeply grateful for their unwavering commitment and generosity, which embody the spirit of this award, created in honor of LBF Hero Cameron Corno and her family. One of the most moving moments of the night was the presentation of the Jack Purssord Courage Award to Ben Bellavia-Cortezi , age 18, honoring his extraordinary strength and resilience throughout his battle with medulloblastoma. Ben’s remarks captivated the audience with their wisdom and grace. He shared, “Every single pediatric brain cancer patient and survivor is so much more than their diagnosis… I believe strongly that with more funding, researchers can develop better treatments- ones that not only save lives but also preserve the quality of those lives.” Ben is applying to colleges for next fall and plans to study mechanical engineering. The funds raised at this year’s Fall Ball will go directly toward groundbreaking research initiatives to discover new treatments and scientific advances for children with pediatric brain cancer. The Lilabean Foundation extends heartfelt thanks to all the sponsors, attendees, volunteers, and donors who made this year’s event such a success. As Ben so wisely put it, “Together, we can give more kids the chance to grow up, chase their dreams, and tell their own story.” Learn More and Get Involved For those unable to attend the Fall Ball, there are still many ways to be part of the Lilabean Foundation’s mission. To learn more about upcoming events, volunteer opportunities, or how to make a donation, please visit www.lilabeanfoundation.com . Together, we can continue to bring hope and funding to pediatric brain cancer research.
SHOW MORE